博九娱乐网

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of products targeting oncology. Its clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of solid tumors indications, including lung, head and neck, and gastric cancers; MGCD516, a kinase inhibitor, which…More is in Phase 1 clinical development for the treatment of patients with non-small cell lung cancer and solid tumors; and Mocetinostat, an orally-bioavailable histone deacetylase inhibitor that is in Phase 2 clinical trial development for patients with bladder cancer, myelodysplastic syndrome, and non-hodgkins lymphoma, principally diffuse large B-cell lymphoma and follicular lymphoma. Mirati Therapeutics, Inc. is headquartered in San Diego, California.